Benefits and harms of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐I) and renin–angiotensin–aldosterone system inhibitors (RAAS‐I) versus SGLT2‐Is alone in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials

INTRODUCTION: It is uncertain if the combination of sodium‐glucose co‐transporter 2 inhibitors (SGLT2‐Is) and renin‐angiotensin‐aldosterone system inhibitors (RAAS‐Is) provides better cardio‐renal clinical outcomes in people with type 2 diabetes mellitus (T2DM) compared with SGLT2‐Is alone. Using a...

Descripción completa

Detalles Bibliográficos
Autores principales: Seidu, Samuel, Kunutsor, Setor K, Topsever, Pinar, Khunti, Kamlesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754244/
https://www.ncbi.nlm.nih.gov/pubmed/34636161
http://dx.doi.org/10.1002/edm2.303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754244/
https://www.ncbi.nlm.nih.gov/pubmed/34636161
http://dx.doi.org/10.1002/edm2.303

Ejemplares similares